Highlander Capital Management LLC lessened its position in shares of Allergan PLC. (NYSE:AGN) by 4.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,086 shares of the company’s stock after selling 200 shares during the quarter. Highlander Capital Management LLC’s holdings in Allergan PLC. were worth $997,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in the company. Veritas Asset Management LLP acquired a new stake in Allergan PLC. in the 1st quarter valued at $761,339,000. Iridian Asset Management LLC CT boosted its stake in Allergan PLC. by 141.3% in the 1st quarter. Iridian Asset Management LLC CT now owns 1,283,833 shares of the company’s stock valued at $306,733,000 after buying an additional 751,848 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Allergan PLC. in the 1st quarter valued at $124,255,000. Vanguard Group Inc. boosted its stake in Allergan PLC. by 2.2% in the 2nd quarter. Vanguard Group Inc. now owns 22,835,689 shares of the company’s stock valued at $5,551,128,000 after buying an additional 482,220 shares in the last quarter. Finally, Blue Ridge Capital L.L.C. boosted its stake in Allergan PLC. by 24.1% in the 1st quarter. Blue Ridge Capital L.L.C. now owns 1,909,900 shares of the company’s stock valued at $456,313,000 after buying an additional 370,400 shares in the last quarter. 81.94% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Highlander Capital Management LLC Sells 200 Shares of Allergan PLC. (AGN)” was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/highlander-capital-management-llc-sells-200-shares-of-allergan-plc-agn/1634341.html.

AGN has been the topic of several recent analyst reports. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $285.00 price target on shares of Allergan PLC. in a research note on Wednesday, September 6th. BidaskClub lowered Allergan PLC. from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Wells Fargo & Company reaffirmed a “buy” rating on shares of Allergan PLC. in a research note on Monday, October 2nd. Deutsche Bank AG reaffirmed a “buy” rating and issued a $273.00 price target (up previously from $265.00) on shares of Allergan PLC. in a research note on Monday, July 17th. Finally, Piper Jaffray Companies set a $227.00 price target on Allergan PLC. and gave the company a “hold” rating in a research note on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have issued a buy rating to the stock. Allergan PLC. has a consensus rating of “Buy” and a consensus target price of $271.44.

Shares of Allergan PLC. (NYSE AGN) opened at 205.52 on Monday. The company has a 50-day moving average price of $215.75 and a 200-day moving average price of $231.93. The company has a market cap of $68.71 billion, a P/E ratio of 6.26 and a beta of 1.15. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $256.80.

Allergan PLC. (NYSE:AGN) last announced its earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The business’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same period in the previous year, the business earned $3.35 EPS. On average, analysts predict that Allergan PLC. will post $16.21 earnings per share for the current year.

Allergan PLC. declared that its Board of Directors has approved a stock buyback program on Monday, September 25th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the company to repurchase up to 2.8% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s management believes its shares are undervalued.

Allergan PLC. Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.